CYTR Related StreetInsider.com Reports
-
CytRx Corp (CYTR) Posts Q1 Loss of 23c/Share
-
CytRx Corp (CYTR) Recommended to Continue Aldoxorubicin Phase 2b to Completion
-
CytRx Corp (CYTR) Posts Q4 Loss of 21c/Share
-
Unusual 11 Mid-Day Movers 03/06: (BLDP) (OSIR) (END) Higher; (ACUR) (AVAV) (AEO) Lower
-
CytRx (CYTR) Files $100M Mixed Shelf
-
CytRx Corp (CYTR) Reports Encouraging Data from Aldoxorubicin Phase 1b/2
-
CytRx Corp (CYTR) Reports Q3 EPS of $0.07
-
CytRx (CYTR) Closes Public Offering After Raising $23 Million
-
CytRx (CYTR) Underwriters Exercise Full 1.2M Common Overallotment
-
Unusual 11 Mid-Day Movers 10/18: (BWEN) (OEH) (GIVN) Higher; (ALGN) (MNKD) (MLNX) Lower
-
Pre-Open Movers 10/18: (GIVN) (SVU) (AEGR) Higher; (ALGN) (MLNX) (IMUC) Lower (more...)
-
CytRx (CYTR) Prices 8M Offering; Sees Gross Proceeds of $20M
-
After-Hours Movers 10/17: (MLNX) (GIVN) (NVAX) (KORS) Higher; (ALGN) (ALB) (AXP) Lower (more...)
-
CytRx (CYTR) Commences Common Offering
-
CytRx (CYTR) Initiates Aldoxorubicin Phase 1b
-
CytRx Corp (CYTR) Updates on Encouraging Data from Aldoxorubicin Phase 1b/2
-
Rodman & Renshaw Starts CytRx Corp (CYTR) at Market Outperform
-
CytRx Corp (CYTR) Posts Q2 GAAP Loss of 63c/Share
-
Morning Movers 07/25: (ZLC) (RVBD) (MITK) (INVN) (LL) Higher; (RSH) (NFLX) (TRIP) (RFMD) Lower
-
CytRx Corp (CYTR) Commences Adoxorubicin Phase 1b in Advanced Solid Tumors
-
CytRx (CYTR) Receives EPO Patent for Linker Platform; Giver 'Aldoxorubucin' Name to INNO-206
-
Morning Movers 06/04: (CBLI) (MTOX) (CRED) Higher; (BONT) (CYTR) Lower
-
CytRx Corp. (CYTR) to Present Encouraging Data from INNO-206 Phase 1b/2 at ASCO
-
CytRx (CYTR) Back in Compliance for Continued Nasdaq Listing
-
CytRx (CYTR) Reports Publication of INNO-206 Findings in Multiple Myeloma
-
CytRx Corp (CYTR) Approves One-for-Seven Reverse Split
-
CytRx Corp (CYTR) Posts Q1 Loss of 7c/Share
-
CytRx (CYTR) Commences INNO-206 Phase 2
-
Notable Analyst Rating Changes 04/23: (JAKK) (RF) (LGF) Upgraded; (PGR) (FSLR) (LEN) Downgraded
-
CytRx (CYTR) Announces Favorable Ruling from NASDAQ Panel, Announces Extension
-
Roth Capital Reinstates Coverage on CytRx Corp (CYTR) at Buy
-
CytRx (CYTR) Receives Nasdaq Listing Requirements Notice
-
CytRx (CYTR) Initiates Dxorubicin Conjugate INNO-206 Phase 2b
-
CytRx (CYTR) Reports Favorable Phase 2 ENABLE in Certain B-CLL Patients
-
CytRx Corp (CYTR) Reports Breakeven Earnings for Q3
-
CytRx (CYTR) Reports Favorable INNO-206 Results from Ongoing Phase 1b/2
-
CytRx Corp (CYTR) Tops Q2 EPS by 3c
-
CytRx Corp (CYTR) Announces INNO-206 Combination Therapy Could Reduce Toxicity and Improve Tumor Response
-
Notable 52-Week Highs and Lows of the Day 07/27: (AMZN) (QCOR) (EXC) High; (JNPR) (DAL) (CYTR) Low
-
Pre-Open Movers 7/27: (AMZN) (LVS) (BA) Higher; (JNPR) (ILMN) (PFCB) Lower (more...)
-
CytRx (CYTR) Sinks Following 39.2M Common Offering, Warrant Pricing
-
CytRx (CYTR) prices 39.2M shares at $0.52/share
-
After-Hours Movers 07/26: (KEYN) (QCOR) (TPX) (ESIO) Higher; (JNPR) (CYTR) (JDAS) (ILMN) Lower
-
CytRx (CYTR) Announces Common Offering
-
CytRx's (CYTR) Tumor-Targeted Doxorubicin Conjugate Delivers Doxorubcin Safely at Higher Doese
-
CytRx's (CYTR) INNO-2006 Granted Ophan Drug Status by FDA
-
Morning Movers 04/28: (VTAL) (LOOP) (SFLY) (FTNT) Higher; (ESLR) (ACLS) (OMX) (AKAM) Lower
-
CytRx's (CYTR) INNO-206 Receives Orphan Drug Designation from U.S. FDA
-
CytRx (CYTR) Aims to Accelerate Enrollment in Tamibarotene Phase 2b with Site Expansion
-
CytRx (CYTR) Gets Stake in ADVENTRX Pharma (ANX) Following SynthRx Acquisition
Back to CYTR Stock Lookup
